Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834966 | 0.86 | OPRL1 (0.61) | OPRM1OPRL1ALDH1A1POLBOPRK1 | |
| SCHEMBL3406087 | 0.85 | CYP3A4 (0.52) | OPRM1OPRL1ALDH1A1CHRM2POLB | |
| SCHEMBL3410504 | 0.84 | CHRM2 (0.50) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL639574 | 0.81 | OPRL1 (0.73) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL17444251 | 0.81 | OPRM1 (0.60) | OPRM1OPRL1CHRM2CHRNB2CHRNA4 | |
| SCHEMBL3409814 | 0.81 | ALDH1A1 (0.51) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL702465 | 0.79 | ALDH1A1 (0.57) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL3406814 | 0.78 | OPRM1 (0.75) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL6422989 | 0.78 | CHRM2 (0.59) | OPRM1OPRL1ALDH1A1LMNACHRM2 | |
| SCHEMBL698466 | 0.78 | ALDH1A1 (0.54) | OPRM1OPRL1ALDH1A1LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | OPRM1 2798/4885OPRL1 2189/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.